<SEC-DOCUMENT>0001213900-23-080744.txt : 20230929
<SEC-HEADER>0001213900-23-080744.hdr.sgml : 20230929
<ACCEPTANCE-DATETIME>20230929074612
ACCESSION NUMBER:		0001213900-23-080744
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20230929
FILED AS OF DATE:		20230929
DATE AS OF CHANGE:		20230929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		231291886

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea185845-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of September 2023 (Report No. 4)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-38041</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCISPARC
LTD.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20
Raul Wallenberg Street, Tower A,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Tel
Aviv 6971916 Israel</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 27, 2023, the
Company issued a press release titled &ldquo;SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split.&rdquo; A copy
of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 29, 2023, SciSparc Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc to Initiate Its Clinical
Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder.&rdquo; A copy of this press release is furnished herewith as Exhibit 99.2
and incorporated by reference herein.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Exhibit 99.1 and the first, second, fourth, fifth and sixth paragraphs and the section titled &ldquo;Forward-Looking Statements&rdquo; of the press
release included as Exhibit 99.2 of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this Report of Foreign Private
Issuer on Form 6-K are incorporated by reference into&nbsp;the Company&rsquo;s registration statements on Form F-3 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm">333-269839</A>,
File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A>,
File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016952/ff32019a1_therapixbio.htm">333-233417</A>, File
No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A> and
File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm">333-255408</A>) and
on Form S-8 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>)
filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: White; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">99.1</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ea185845ex99-1_scisparc.htm">Press release issued by SciSparc Ltd. dated September 27, 2023, titled &ldquo;SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split.&rdquo;</A></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea185845ex99-2_scisparc.htm">Press release issued by SciSparc Ltd. dated September 29, 2023, titled &ldquo;SciSparc to Initiate Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder.&rdquo;</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc
    Ltd.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 29, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Oz Adler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz
    Adler</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea185845ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. DATED SEPTEMBER 27, 2023, TITLED "SCISPARC ANNOUNCES EXPECTED IMPLEMENTATION OF 1-FOR-26 REVERSE SHARE SPLIT."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Announces Expected Implementation of 1-for-26 Reverse Share
Split</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Following the reverse share split, the Company
will have approximately 521,090 Ordinary Shares issued and outstanding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- &nbsp;SciSparc
Ltd. (Nasdaq: SPRC) (&ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty clinical-stage pharmaceutical company focusing on
the development of therapies to treat disorders and rare diseases of the central nervous system, announces today that its previously
announced reverse share split of its issued and outstanding ordinary shares, no par value at a ratio of 1-for-26, is expected to be implemented
after market close today. The Company&rsquo;s Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at
the market open on&nbsp;September 28, 2023, under the Company&rsquo;s existing trading symbol &ldquo;SPRC&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reverse stock split was approved by the Company&rsquo;s shareholders
at the Company&rsquo;s Annual Meeting of Shareholders held on&nbsp;August 18, 2023&nbsp;to be effected in the board of director&rsquo;s
discretion within approved parameters.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the implementation of the reverse split, the Company&rsquo;s
authorized share capital will not be adjusted under the Company&rsquo;s articles of association, as currently in effect (the &ldquo;Articles&rdquo;),
which as of the date hereof consists of 75,000,000 Ordinary Shares, no par value. The reverse split will adjust the number of issued
and outstanding Ordinary Shares of the Company from approximately 13.5 million Ordinary Shares to approximately 521,090 Ordinary Shares,
subject to any further adjustments based on the treatment of fractional shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No fractional Ordinary Shares will be issued as a result of the reverse
split. In accordance with the Company&rsquo;s Articles, all fractional shares shall be rounded up to the nearest whole ordinary share,
such that only shareholders holding fractional consolidated shares of one half of one whole share or more shall be entitled to receive
one consolidated share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares
issuable upon the exercise of all outstanding options or warrants entitling the holders to purchase Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;SciSparc&nbsp;Ltd. (Nasdaq: SPRC):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development
programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer&rsquo;s
disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also
owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Amazon.com Marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the
meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities
laws. For example, SciSparc is using forward-looking statements when it discusses the implementation of the reverse share split. Because
such statements deal with future events and are based on SciSparc&rsquo;s current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other
risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on
Form 20-F filed with the SEC on&nbsp;May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except
as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which
speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Contact:<BR>
IR@scisparc.com<BR>
Tel: +972-3-6167055</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea185845ex99-2_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. DATED SEPTEMBER 29, 2023, TITLED SCISPARC TO INITIATE ITS CLINICAL TRIAL WITH SCI-210 IN PEDIATRICS WITH AUTISM SPECTRUM DISORDER.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><IMG SRC="image_001.jpg" ALT="A logo with a dotted line&#10;&#10;Description automatically generated" STYLE="height: 150px; width: 150px"></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt">SciSparc
Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder</FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEL
AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (&ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous
system, today announced the initiation of a pivotal clinical trial for its drug candidate, SCI-210, at the Soroka University Medical
Center. SCI-210 is designed to help control symptoms of Autism Spectrum Disorder (&ldquo;ASD&rdquo;) and is an innovative proprietary
combination of cannabidiol (&ldquo;CBD&rdquo;) and SciSparc&rsquo;s Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide&trade;.</FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as
a randomized, double-blind, placebo-controlled trial with a cross-over study, the trial will span 20 weeks and involve 60 children between
5-18 years old. The trial&rsquo;s primary efficacy endpoints include three rigorous assessments: the Aberrant Behavior Checklist-Community
(ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement (CGI-I) scale, administered by healthcare professionals; and
the determination of the effective therapeutic dosage.</FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz
Adler, Chief Executive Officer of SciSparc weighed in on the significance of the trial, stated, &ldquo;The initiation of this clinical
trial signifies a major leap forward in our collective effort to understand and effectively treat ASD. Partnering with the National Autism
Research Center, Israel&rsquo;s foremost authority on autism research, underscores our unwavering commitment to scientific rigor and patient
safety. Our goals are to create an effective and safe treatment for ASD and to improve the quality of life for these children and their
families. We are optimistic that SCI-210 could be a game-changer in ASD treatment.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial was designed in collaboration with the National Autism Research Center, Israel&rsquo;s leading institution for autism research.</FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Soroka University Medical Center, one of the most prestigious healthcare institutions in Israel, will host the study. This location offers
an advanced clinical setting, coupled with a multidisciplinary team of experts in neurology and developmental disorders, which the Company
believes demonstrates the trial&rsquo;s high scientific and ethical standards.</FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASD
is a neurodevelopmental condition that profoundly impacts social interaction and communication skills. The term &ldquo;spectrum&rdquo;
in Autism Spectrum Disorder encapsulates the wide array of symptoms and severity levels associated with this complex condition.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About&nbsp;SciSparc&nbsp;Ltd.
(Nasdaq: SPRC):</B></FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer&rsquo;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale
of hemp seeds&rsquo; oil-based products on the Amazon.com&nbsp;Marketplace.</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements:</B></FONT></P>

<P STYLE="text-align: justify; font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses:
the goals and objectives of the SCI-210 clinical trial; and the Company&rsquo;s optimism that SCI-210 could be a game-changer in ASD
treatment. Because such statements deal with future events and are based on SciSparc&rsquo;s current expectations, they are subject to various
risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or
implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject
to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on
Form 20-F filed with the SEC on&nbsp;May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission. Except
as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which
speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 11.5pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Contact:<BR>
<FONT>IR@scisparc.com</FONT><BR>
Tel: +972-3-6167055</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "7 )<# 2(  A$! Q$!_\0
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M=3GGCUSXCZQIL++=>,U\*(J7NE>%;79+J5Q)&,^6)-P!]I5\5?'O]O3]D_\
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M#^-7BSQ'XEU671_!/@#1?AZSR3WWBKQA>+"_ANT29S<V]S%<&54#-7RMX?\
M^"D/_!1G2-9\!>-OC7_P2 ^*W@[]GKXG>)=$T&UU/X<_&#P7\6/V@/AW9>([
MJ&W\/>*_BC\%M.T72CI5B?M4,_B:UL?%%[?>$+99UU&+[1:RQM@_\%[?!'CZ
MW^#W[)7[3WAOP9XB^)'@/]B/]LKX9_M"?&?X7>$M.;6-3\1?"C08KS2=<\1V
M^BQ G4O^$ CN_P#A*8[%1Y@%IB/B)F'T?XL_X+5?\$U=$^$/A/XO:'^T_P"
M_BG:_$*XT;3_  %\,/A%J=C\1?C=XSU_Q!>VEMI_A.Q^$&CM+XTL_$J7-U&N
MK:7J]AI"Z9# \L]P@PS 'ZT)N*(6&&*KN'/#8&1R2>OJ2?4TZL[2-0&K:3I>
MJK;7EFNIZ=9:@MIJ-LUGJ%J+VVBN1;7]FS,UK>0"3RKJV9F:"=7B+$H2=&@
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MG[</[2/[/'Q&\$?!GXM_"KX$_LT:CX\\<Z]\2OC=X6O/AMXD^('CKQ+X6O?
M^E_#SP+X!GO;C6KG0X+36;[Q1XU\1ZS;VNF3ZC8^'[&ULWFM9V'[ (H"@8'*
MJ&P ,X&.0 !^&  .  .*^.?V"/&'Q2^('[('P$\;_&:XOM0^('B#P)8WM]K6
MLZ>^E>(_$&B&YG'A;Q#XDTQTC_LSQ1X@\-+I.K>(+%8XECU>\NUV @ ?9- !
M1110 5XC\:/C;\*OV=_AQXD^+OQQ\>Z/\/OA]X4MU?5_$?B"Y@MH!=SR"TTV
MRL(H/]+O=?U2>1+/2="TJ*XU'4+IXX[>WDF< >W5_ U_P<^?MBZKHG_!4'_@
MG/\ LT>-[F\M/V:_ACXR^$GQX^(VA_;&M=(\5ZYJOQ1LHKC6M;V,L-Q8^%-!
MTHLL5XLD,(:]D4(TFZ@#^[_POK]IXK\-Z'XETY+V'2]?T>QUC3QJ,$MEJ(L=
M0LXKRRGGM)U6>WFEMIHI9+>Y1)X78QS1K(KH/./CY\6(O@3\$?BK\99O#NM>
M+X?A9X \1>.;CPUX?\H:YX@MO#6G3ZG<:5HXEM[N)M0NHH"D -G*IE=%P=PK
MU?2]1L-6TZRU?2[VWO\ 2-5L;*_TF[MBKV]U97UM'=V=S;R# :&YMIH983@
MQ.C# K1DABGB>&>*.:*6-HI8I8TDCDCD7;)&Z."CHZ_*Z,"K#@@B@#^+;4O^
M#RSX-Z#H\FJZ[_P3J_:JTBSC&9;S5O$7A^RLHY63S(T;4;SP[!:1[L@KEE4
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M=PT*--&LVU?-"2%E$FU=X&[ SBB@"W1110 4444 %%%% !7Q-_P484#]@?\
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MIPQ@8QC QCD8[8/<>E(%55"*JA -H4 !0H& H4#  '& ,8XI0         ,
M <  #@ #H* %HHHH *_+S]LK]C3XD?M4?MA_\$^?'6HZ[X9B_9@_93^(_CGX
M_?$#P9>M<+XE\2_''2?#BZ!\"=2L$4FVFTKPW?ZIKFI7:3J?+F$;IMD937U[
M^T]^T5\+_P!DWX$?$_\ :,^,NN'0?AQ\(_#5]XE\2W<$;7FIW4-N5$.AZ)8"
M: ZGX@U^YFL])T2PA8SSZC>VT,(9WQ7<?!_XD:7\8_A;\.OBYHFD>(M$TCXD
M^"O#7C32M$\6Z.^A^*M,TWQ3I%GKEC9>(=)G GTO6+6UO8XM2T^7Y[.\6>W<
M;XVH ]-7D YSP.3U/'4T4BC:JJ.@4 8Z<#'%% #J*** "BBB@ HHHH *, =!
MBBB@ HHHH **** "BBB@ HK,EF!D*,[[C(8HMC8;[2$WB*%-JJX$),DC3$QH
M1N.0"1^;'A/_ (*3^ /C#^W3J7[$OP \&>(OC7:?#+PKK>J?M.?'GPSJ5O'\
M)_@#XC6T,_A#X>:OX@2(VWB7QUXJN$N;>XTCP_=SW&@)"LMZL8$PC /*?VX_
MV+_CA^W3^UU^S7X(^(Q\-V/_  3E^ UU%\??B7X?@UI-1\3_ +0/[0/A_4@O
MPZ^&7BCPLJ1"R^'W@AEM?&\\EV;NQUW43%;30^=9Q%?V+@P88<",#RH\",YC
M *# C) S&!@*<#*XX'2E5(RH.%?.QMY527*@;7)  +=PV..V*DH .G2BBB@
MHHHH **** "BBB@ HHHH **** "BJ+"0CEI,@L0KC+)SP7:&2./R\#*AR"1]
MXYS7 7OQ0^'^F^,-$^'U]X_\(6?CWQ ER_A[P?<^)='C\0:['9V\EY?R:=X?
M6^DUBY%K9I).SB(QA4+*0JG !Z;7.:GJ^G:2UO)J.JV.EB^OX-*TLZK>0Z=#
M=:M>;X[33;9KJYC_ +1O;YB_V6UM0\\CIMC1F&%\O^/6K?&W2?@]\1=4_9U\
M,^$/%OQOLO#>H-\,?#OQ#UK4] \&:QXF98CI\'BK4[2T>XT[2T!>6YNK;+@P
MB%9 9B:_)3X*?\$M?C5\6_BAX#_:>_X*H?M4ZQ^TU\6/ .M:9XS^%WP#^%4^
MM?#7]DSX(^++1EO-/U?1?#&F7%AJOQ$\3Z3.XCTOQ/XN>&4JGF)9SK,30!^I
MW[2GP<U?]HKX&_$GX*Z+\4_'7P2O?B/H=UH,GQ/^&<]KI_COPQ9WKP"[U#P]
M=WSL;.:[TY)-*EN(#%>6[3236YA<!JY_]DW]D3X$?L6?!3PY\#OV?/!VG^#_
M  7HHDNM0N]ZZAX@\6>);P"35?'7C3Q'.BZGXF\9Z_.#<:CK%]<S2&:=HH76
MV2*-?JM4C=58H#G;("Z -OVC#L&4$28 !) 88Q@8P)-JY#;1N V@X&0N0=H/
M4#(!QTR!Z4 (ARBDJ4)4$H<97(!VG'&5Z''''%.HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^&OVW?V*M$_;:\$^$_ OB_P".O[1_P0\)>%O$USXIU]/V
M</BA=_"K6/'5H=.>T'AKQCK.F6=]J-[X=1B;L6%C);LT^V0NDBJ5\F_95_X)
M%?L"?LA>-=.^,GP8^",=]\9H;*XMX?C1\1O%OC/XH?$WR-1MI;2\:U\2?$#Q
M#J]UI+WEM<30SOI(T_?'//$8EBD* HH _3E(HPJ9C7<L2Q@L S!!M.PL=Q(W
H*"?F() .2>:D"J!@* !R    3R3QZFBB@!:*** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 )8# 2(  A$! Q$!_\0
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M"0GY(54M(XQW Q^= '2T444 %%%% !1110 4444 %<Q\1E9_AQXA55+,;"4
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5% &A1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
